This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abiomed Announces Publication Of PROTECT II Study In Circulation: Journal Of The American Heart Association

DANVERS, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that results from its PROTECT II study will be published in an upcoming print edition of Circulation, the journal of the American Heart Association. The study, "A Prospective Randomized Clinical Trial of Hemodynamic Support with Impella® 2.5 versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention: the PROTECT II Study," was accepted for publication on August 20, 2012 and published online on August 30, 2012 via the following link: http://m.circ.ahajournals.org/content/early/2012/08/30/CIRCULATIONAHA.112.098194

The PROTECT II study was a prospective multicenter randomized trial that was "designed to assess whether a high-risk percutaneous revascularization strategy with the support of the Impella 2.5 device would result in better outcomes than a revascularization strategy with intra aortic balloon pump (IABP) support."

"Today marks a very significant milestone in providing new clinical insight for cardiovascular disease patients considered too risky for conventional surgery. The PROTECT II publication in Circulation underscores the importance of this study's observations to the clinical community," said William W. O'Neill, M.D., principal investigator of the PROTECT II trial and medical director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit.

Study authors include William W. O'Neill, M.D.; Neal S. Kleiman, M.D.; Jeffrey Moses, M.D.; Jose P.S. Henriques, M.D., Ph. D.; Simon Dixon, MBChB; Joseph Massaro, Ph. D.; Igor Palacios, M.D.; Brijeshwar Maini, M.D.; Suresh Mulukutla, M.D.; Vladimir Dzavik, M.D.; Jeffrey Popma, M.D.; Pamela S. Douglas, M.D.; and Magnus Ohman, M.D.  Circulation has the highest ranking impact factor among journals in the Cardiac & Cardiovascular Systems category.

"PROTECT II is a landmark clinical trial and we are grateful to Dr. O'Neill and his colleagues for leading this study," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "The peer-reviewed publication of PROTECT II in the esteemed Circulation journal is a notable achievement for Abiomed. Most importantly, we believe that this study will advance the treatment for patients with heart failure."

These data in PROTECT II have been collected, validated, and monitored by a third party academic research organization and the major adverse events (MAE) were assessed at 30 and 90 days. Additionally, all hospital charges were tracked by an independent health economic organization in coordination with the study.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs